Toronto, Ontario – January 24, 2022 – PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (FSE: G111) (“PharmaDrug” or the “Company“), a specialty pharmaceutical company focused on the development and commercialization of controlled-substances and natural medicines such as...
Vantage pursues Drug Master Files with the FDA to support the quality and safety of its products Greeley, Colorado, Jan. 24, 2022 – Vantage Hemp Co. (“Vantage” or the “Company”), an industry-leading manufacturer of pharmaceutical-grade CBD products, today...
Toronto, Ontario – January 20, 2022 – PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (“PharmaDrug” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of controlled-substances and...
Approximately 700 subjects participated in the enrollment period Expected to begin subject enrollment in Turkey by mid-February Expected to complete enrollment in Q1-2022 TORONTO, Jan. 06, 2022 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB:...
Toronto, Ontario – December 13, 2021- PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (“PharmaDrug” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of controlled-substances and natural...
